Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept in Anemia and Low/Int-1 Risk MDS or CMML
NCT01736683Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2012
- Primary completion
- Apr 2018
- Countries
- 2
01
Overview
A Phase 2 trial of sotatercept in anemia, myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Merck & Co.. Started Nov 2012; status: completed.
02
Drugs
sotatercept
03
Conditions
anemiamyelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01736683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01736683.